Abbott Laboratories — Apr 16, 2026 release

f $1.15 reflects growth of 6 percent – Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market – Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 – Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences ABBOTT PARK, Ill., April 16, 2026 — Abbott today announced financial results for the first quarter ended March 31, 2026. • First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis. • First-quarter GAAP diluted EPS of $0.61 and adjusted diluted EPS of $1.15, which excludes specified items and reflects growth of 6 percent. • On March 23, 2026, Abbott completed its acquisition of Exact Sciences, establishing the company as a leader in the oncology diagnostics market and adding a new high-growth vertical to Abbott's portfolio. • Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% 1 . • Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences. • In January, Abbott announced a collaboration with AtaCor Medical to develop a next-generation extravascular implantable cardioverter (EV-ICD) system designed to deliver defibrillation therapy to people living with life-threatening heart rhythm